Rapid pulmonary delivery of inhaled tobramycin for pseudomonas infection in cystic fibrosis: A pilot project

Pediatric Pulmonology

Volumn 43, Issue 8, 2008, Pages 753-759

  Coates, Allan L ^a,c   Green, Maria ^a   Leung, Kitty ^a   Chan, Jeffrey ^a   Ribeiro, Nancy ^a   Louca, Emily ^a   Ratjen, Felix ^a   Charron, Martin ^a   Tservistas, Markus ^b   Keller, Manfred ^b  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b Pari Pharma GmbH   (Germany)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Aerosol; Drug deposition; Inhaled antibiotics; Nebulization; Nuclear medicine

Indexed keywords

TOBRAMYCIN; TOBRAMYCIN SULFATE;

ALGORITHM; ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; GRAM NEGATIVE INFECTION; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; MEDICAL NEBULIZER; MUCOCILIARY CLEARANCE; NORMAL HUMAN; PILOT STUDY; PRIORITY JOURNAL; SCINTILLATION CAMERA;

ADMINISTRATION, INHALATION; ADULT; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PILOT PROJECTS; PSEUDOMONAS INFECTIONS; TIME FACTORS; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 49649099230     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.20850     Document Type: Article

References (38)

1. Ramsey BW, Burns J, Smith AL. Safety and efficacy of tobramycin solution for inhalation in patients with cystic fibrosis: the results of two Phase III placebo controlled clinical trials. Pediatr Pulmonol 1997;14:S137-S138.
2. MacLusky IB, Gold R, Corey ML, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol 1989;7:42-48.
3. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt PW, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey B. Significant microbiological effects of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167:841-849.
4. Hodson ME, Gallagher CG, Govan JRW. A randomized clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2003;20:658-664.
5. Abbott J, Dodd M, Webb K. Ways of coping with cystic fibrosis: implications for treatment adherence. Disabil Rehabil 2001;23:315-324.
6. Geller DE, Rosenfeld M, Waltz DA, Wilmott RW. AeroDose TOBI Study Group. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery device. Chest 2003;123:28-36.
7. Mukhopadhyay S, Staddon GE, Eastman C, Palmer M, Rys Davies E, Carswell F. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Respir Med 1994;88:203-211.
8. Coates G, O'Brodovich HM. Measurement of pulmonary epithelial permeability with 99mTc-DTPA aerosol. Semin Nucl Med 1986;XVI:275-284.
9. O'Brodovich HM, Coates G, Kay J, Muysson D. Simultaneous measurement of lung clearance rates for Tc- and In-DTPA in normal and damaged lungs. J Appl Physiol 1989;66:2293-2297.
10. Regnis JA, Robinson M, Bailey DL, Cook P, Hooper P, Chan H-K, Gonda I, Bye PTP. Mucociliary clearance in patients with cystic fibrosis and in normal subjects. Am J Respir Crit Care Med 1994;150:66-71.
11. Robinson M, Eberl S, Tomlinson C, Daviskas E, Regnis JA, Bailey DL, Torzillo PJ, Menache M, Bye PTP. Regional mucociliary clearance in patients with cystic fibrosis. J Aerosol Med 2000;13:73-86.
12. Coates AL, Green M, Leung K, Louca E, Tservistas M, Chan J, Ribeiro N, Charron M. The challenges of quantitative measurement of lung deposition using 99mTc-DTPA from delivery systems with very different delivery times. J Aerosol Med 2007;20:320-330.
13. Coates AL, MacNeish CF, Lands LC, Meisner D, Kelemen S, Vadas EB. A comparison of the availability of tobramycin for inhalation from vented versus unvented nebulizers. Chest 1998;113:951-956.
14. Lass JS, Sant A, Knoch M. New advances in aerosolised drug delivery: vibrating membrane nebuliser technology. Expert Opin Drug Deliv 2006;3:696-702.
15. Knoch M, Keller M. The customized electronic nebulizer, eFlow: a new category of liquid aerosol delivery system. Expert Opin Drug Deliv 2005;2:377-390.
16. Ilowite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamycin in cystic fibrosis. Am Rev Respir Dis 1987;136:1445-1449.
17. Coates AL, MacNeish CF, Dinh L, Rollin T, Gagnon S, Ho SL, Lands LC. Accounting for radioactivity before and after nebulization of tobramycin to insure accuracy of quantification of lung deposition. J Aerosol Med 2000;13:169-178.
18. Tservistas M, Balke A, Stempfle P, Reul K, Walther E, Keller M. Nebulizer systems and formulation characteristics: two factors affecting in vitro inhaler system performance for cystic fibrosis treatment. Drug Deliv Lung 2003;14:176-179.
19. Kwong WTJ, Ho SL, Coates AL. Comparison of nebulized particle size distribution with Malvern laser diffraction analyzer versus Andersen cascade impactor and low-flow Marple personal cascade impactor. J Aerosol Med 2000;13:303-314.
20. Mitchell JP, Nagel MW, Nichols S, Nerbrink O. Laser diffractometry as a technique for rapid assessment of aerosol particle size from inhalers. J Aerosol Med 2006;19:409-433.
21. Katz SL, Adatia I, Louca E, Leung K, Humpl T, Reyes JT, Coates AL. Nebulized therapy for childhood pulmonary hypertension: an In vitro model. Pediatr Pulmonol 2006;41:666-673.
22. O'Callaghan C, Clarke AR, Milner AD. Inaccurate calculation of drug output from nebulisers. Eur J Pediatr 1989;148:473-474.
23. Coates AL, MacNeish CF, Lands LC, Smountas A, Meisner D, Kelemen S, Vadas EB. Factors influencing the rate of drug output during the course of wet nebulization. J Aerosol Med 1998;11:101-111.
24. Kwong E, MacNeish CF, Meisner D, Kelemen S, Vadas EB, Coates AL. The use of osmometry as a means of determining changes in drug concentration during jet nebulization. J Aerosol Med 1998;11:89-100.
25. Barends DM, Zwaan CL, Hulshoff A. Microdetermination of tobramycin in serum by high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1981;225:417-426.
26. Mants LE, Wilcox MJ. Alltech Associates, Inc. 2051 Waukegan Road Deerfield IL 60015 USA 2000. Reversed-Phase HPLC Analysis of Aminoglycoside Antibiotics: Using Evaporative Light Scattering Detection. 2000.
27. Macey DJ, Marshall R. Absolute quantitation of radiotracer uptake in the lungs using a gamma camera. J Nucl Med 1982;23:731-735.
28. Pitcairn GR, Newman SP. Tissue attenuation corrections in gamma scintigraphy. J Aerosol Med 1997;10:187-198.
29. Smaldone GC, Fuhrer J, Steigbigel RT, McPeck M. Factors determining pulmonary deposition of aerosolized pentamidine in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1991;143:727-737.
30. Gagnadoux F, Diot P, Marchand S, Thompson R, Dieckman K, Lemarié E, Varaigne F, Maurage C, Baulieu JL, Rolland JC. Déposition pulmonaire des aérosols de colistine dans la mucoviscidose: comparaison d'un nébuliseur ultrasonique et d'un pneumatique. Rev Mal Resp 1996;13:55-60.
31. Laube BL, Jashnani R, Dalby RN, Zeitlin PL. Targeting aerosol deposition in patients with cystic fibrosis: effects of alteration in particle size and inspiratory flows. Chest 2000;118:1069-1076.
32. Cipolla DC, Clark AR, Chan H-K, Gonda I, Shire SJ. Assessment of aerosol delivery systems for recombinant human deoxyribonuclease. STP Pharm Sci 1994;4:50-62.
33. Coates AL, MacNeish CF, Allen PD, Ho SL, Lands LC. Do sinusoidal models of respiration accurately reflect the respiratory events of cystic fibrosis patients breathing on nebulizers? J Aerosol Med 1999;12:265-273.
34. Byrne NM, Keavey PM, Perry JD, Gould FK, Spencer DA. Comparison of lung deposition of colomycin using the HaloLite and Pari LC Plus nebulizers in patients with cystic fibrosis. Arch Dis Child 2003;88:715-718.
35. Newman SP, Pellow PGD, Clay MM, Clarke SW. Evaluation of jet nebulisers for use with gentamycin solution. Thorax 1985;40:671-676.
36. Clay MM, Pavia D, Newman SP, Lennard-Jones T, Clarke SW. Assessment of jet nebulisers for lung aerosol therapy. Lancet 1983;ii:592-594.
37. Coates AL, MacNeish CF, Meisner D, Kelemen S, Thibert R, MacDonald J, Vadas EB. The choice of jet nebulizer, nebulizing flow and the addition of Ventolin Respiratory Solution affects tobramycin aerosols used in cystic fibrosis. Chest 1997;111:1206-1212.
38. Sorenson JA, Phelps DL. Problems in radioactive detection and measurement. In: Anonymous physics in nuclear medicine. 1st edition. Orlando, San Diego, New York: Grune and Gratton Inc; 1980. pp. 208-228.